| 1.22 0.01 (0.83%) | 05-12 13:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.61 | 1-year : | 1.88 |
| Resists | First : | 1.37 | Second : | 1.61 |
| Pivot price | 1.22  |
|||
| Supports | First : | 1.11 | Second : | 0.94 |
| MAs | MA(5) : | 1.18 |
MA(20) : | 1.2  |
| MA(100) : | 1.5 |
MA(250) : | 3.5 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 70.1 |
D(3) : | 62 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 11 | Low : | 0.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TRVN ] has closed above bottom band by 48.5%. Bollinger Bands are 35.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.22 - 1.23 | 1.23 - 1.23 |
| Low: | 1.14 - 1.14 | 1.14 - 1.15 |
| Close: | 1.21 - 1.22 | 1.22 - 1.23 |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Tue, 06 May 2025
Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Wed, 15 Jan 2025
Trevena discontinues OLINVYK injection sales - Investing.com
Tue, 14 Jan 2025
Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
Fri, 04 Oct 2024
Trevena Announces Receipt of Nasdaq Delisting Notification - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 812800 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 16 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.175e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 970.6 % |
| Return on Equity (ttm) | -62.4 % |
| Qtrly Rev. Growth | 546000 % |
| Gross Profit (p.s.) | 66.51 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.2093e+006 |
| Qtrly Earnings Growth | -48.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.04 |
| Dividend | 0 |
| Forward Dividend | 59360 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|